Orphan drug designation has been a critical driver in the Duchenne Muscular Dystrophy Treatment Market. This status offers incentives like tax credits, market exclusivity, and reduced regulatory fees, encouraging pharmaceutical companies to invest in rare disease research. Several DMD therapies have already benefited from this designation, accelerating their journey from lab to mar... https://www.marketresearchfuture.com/reports/duchenne-muscular-dystrophy-treatment-market-21953